Download PDF
Am J Perinatol 2024; 41(S 01): e2555-e2561
DOI: 10.1055/a-2125-1330
Original Article

Serum ADAMTS-9 Level in Newborn Babies with Congenital Heart Disease

Cem Becerir 
1   Department of Neonatology, Ankara City Hospital, Neonatal Intensive Care Unit, University of Health Sciences, Ankara, Turkey
,
Cüneyt Tayman 
1   Department of Neonatology, Ankara City Hospital, Neonatal Intensive Care Unit, University of Health Sciences, Ankara, Turkey
,
Abdullah Kurt 
2   Department of Neonatology, Yildirim Beyazit University Faculty of Medicine, Ankara Turkey
,
Ufuk Çakır 
1   Department of Neonatology, Ankara City Hospital, Neonatal Intensive Care Unit, University of Health Sciences, Ankara, Turkey
,
İsmail Koyuncu 
3   Department of Medical Biochemistry, Harran University, Urfa, Turkey
,
Burak Ceran 
1   Department of Neonatology, Ankara City Hospital, Neonatal Intensive Care Unit, University of Health Sciences, Ankara, Turkey
,
Kenan Toprak 
4   Cardiology Department, Faculty of Medicine, Harran University, Şanlıurfa, Turkey
,
Murat Kızılgün 
5   Department of Medical Biochemistry, Sağlık Bilimleri Üniversitesi Gülhane Tıp Fakültesi, Health Science University Ankara, Turkey
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective A Disintegrin and Metalloproteinase with Thrombospondin-9 (ADAMTS-9), one of the ADAMTS enzymes, is expressed in all fetal tissues, unlike other ADAMTS enzymes, and is thus thought to play a role in fetal development. In this context, the objective of this study is to investigate the relationship between ADAMTS-9 activity and the development of congenital heart diseases (CHD) with a view to using ADAMTS-9 level as a biomarker for CHDs.

Study Design Newborns diagnosed with CHD and healthy newborns were included in the study as the CHD and control groups, respectively. Gestational age, maternal age, and mode of delivery information pertaining to the mothers and Apgar score and birthweight information pertaining to the newborns were recorded. Blood samples were taken from all newborns to determine their ADAMTS-9 levels in the first 24 hours of life.

Results Fifty-eight newborns with CHD and 46 healthy newborns were included in the study. Median ADAMTS-9 levels were 46.57 (interquartile range [IQR]: 33.31 [min: 26.92, max: 124.25]) and 23.36 (IQR: 5.48 [min: 11.7, max: 37.71]) ng/mL in the CHD and control groups, respectively. ADAMTS-9 levels in the CHD group were statistically significantly higher than in the control group (p = 0.000). ADAMTS-9 levels of the CHD and control groups were analyzed by the receiver operating characteristics curve. The area under the curve value for ADAMTS-9 levels of >27.86 ng/mL as the cut-off value for predicting the development of CHD in newborns was 0.836 (95% confidence interval [CI]: 0.753–0.900, p = 0.0001). ADAMTS-9 levels of >27.86 ng/mL were determined to predict the development of CHD in newborns with a sensitivity of 77.78% (95% CI: 65.5–87.38) and a specificity of 84.78% (95% CI: 71.1–93.60).

Conclusion In conclusion, it was found that the serum ADAMTS-9 levels were significantly higher in newborns with CHD than in healthy newborns. In parallel, ADAMTS-9 levels above a certain cut-off value were associated with CHD.

Key Points

  • ADAMTS-9 is expressed in fetal tissues.

  • Its level increases in congenital heart diseases.

  • It can be used as a biochemical marker in diagnosis.

Keywords

ADAMTS-9 - ADAMTS enzymes - congenital heart diseases - newborn

Authors' Contributions

C.B., A.K., B.C., and C.T. conceptualized and designed the study, drafted the initial manuscript. C.T., I.K., and C.B. carried out the initial analyses, reviewed, and revised the manuscript. U.C., K.T., and M.K. supervised the statistics. C.T., K.T., and A.K. made critical revision of the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. The authors declare that all data were generated in-house and that no paper mill was used. All authors read and approved the manuscript and all data were generated in-house and that no paper mill was used




Publication History

Received: 13 December 2022

Accepted: 06 July 2023

Accepted Manuscript online:
07 July 2023

Article published online:
14 August 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Jenkins KJ, Correa A, Feinstein JA. et al; American Heart Association Council on Cardiovascular Disease in the Young. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115 (23) 2995-3014
    CrossrefPubMedSearch in Google Scholar
  • 2 Pierpont ME, Brueckner M, Chung WK. et al; American Heart Association Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Genomic and Precision Medicine. Genetic basis for congenital heart disease: revisited: a scientific statement from the American Heart Association. Circulation 2018; 138 (21) e653-e711
    CrossrefPubMedSearch in Google Scholar
  • 3 Liu Y, Chen S, Zühlke L. et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. Int J Epidemiol 2019; 48 (02) 455-463
    CrossrefPubMedSearch in Google Scholar
  • 4 Cowan JR, Ware SM. Genetics and genetic testing in congenital heart disease. Clin Perinatol 2015; 42 (02) 373-393 , ix
    CrossrefPubMedSearch in Google Scholar
  • 5 Hoang TT, Goldmuntz E, Roberts AE. et al. The congenital heart disease genetic network study: cohort description. PLoS One 2018; 13 (01) e0191319
    CrossrefPubMedSearch in Google Scholar
  • 6 Zaidi S, Brueckner M. Genetics and genomics of congenital heart disease. Circ Res 2017; 120 (06) 923-940
    CrossrefPubMedSearch in Google Scholar
  • 7 Stanton H, Melrose J, Little CB, Fosang AJ. Proteoglycan degradation by the ADAMTS family of proteinases. Biochim Biophys Acta 2011; 1812 (12) 1616-1629
    CrossrefPubMedSearch in Google Scholar
  • 8 Vázquez F, Hastings G, Ortega MA. et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999; 274 (33) 23349-23357
    CrossrefPubMedSearch in Google Scholar
  • 9 Colige A, Vandenberghe I, Thiry M. et al. Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. J Biol Chem 2002; 277 (08) 5756-5766
    CrossrefPubMedSearch in Google Scholar
  • 10 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (06) 1662-1666
    CrossrefPubMedSearch in Google Scholar
  • 11 Liu CJ, Kong W, Ilalov K. et al. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J 2006; 20 (07) 988-990
    CrossrefPubMedSearch in Google Scholar
  • 12 Liu CJ, Kong W, Xu K. et al. ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J Biol Chem 2006; 281 (23) 15800-15808
    CrossrefPubMedSearch in Google Scholar
  • 13 Somerville RP, Longpré JM, Apel ED. et al. ADAMTS7B, the full-length product of the ADAMTS7 gene, is a chondroitin sulfate proteoglycan containing a mucin domain. J Biol Chem 2004; 279 (34) 35159-35175
    CrossrefPubMedSearch in Google Scholar
  • 14 Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC, Maki RA. ADAMTS9, a novel member of the ADAM-TS/ metallospondin gene family. Genomics 2000; 67 (03) 343-350
    CrossrefPubMedSearch in Google Scholar
  • 15 Kern CB, Wessels A, McGarity J. et al. Reduced versican cleavage due to Adamts9 haploinsufficiency is associated with cardiac and aortic anomalies. Matrix Biol 2010; 29 (04) 304-316
    CrossrefPubMedSearch in Google Scholar
  • 16 Jerves T, Beaton A, Kruszka P. The genetic workup for structural congenital heart disease. Am J Med Genet C Semin Med Genet 2020; 184 (01) 178-186
    CrossrefPubMedSearch in Google Scholar
  • 17 Jin SC, Homsy J, Zaidi S. et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet 2017; 49 (11) 1593-1601
    CrossrefPubMedSearch in Google Scholar
  • 18 Manheimer KB, Richter F, Edelmann LJ. et al. Robust identification of mosaic variants in congenital heart disease. Hum Genet 2018; 137 (02) 183-193
    CrossrefPubMedSearch in Google Scholar
  • 19 Lockhart M, Wirrig E, Phelps A, Wessels A. Extracellular matrix and heart development. Birth Defects Res A Clin Mol Teratol 2011; 91 (06) 535-550
    CrossrefPubMedSearch in Google Scholar
  • 20 Zhang P, Shen M, Fernandez-Patron C, Kassiri Z. ADAMs family and relatives in cardiovascular physiology and pathology. J Mol Cell Cardiol 2016; 93: 186-199
    CrossrefPubMedSearch in Google Scholar
  • 21 Sandy JD, Westling J, Kenagy RD. et al. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem 2001; 276 (16) 13372-13378
    CrossrefPubMedSearch in Google Scholar
  • 22 Russell DL, Doyle KM, Ochsner SA, Sandy JD, Richards JS. Processing and localization of ADAMTS-1 and proteolytic cleavage of versican during cumulus matrix expansion and ovulation. J Biol Chem 2003; 278 (43) 42330-42339
    CrossrefPubMedSearch in Google Scholar
  • 23 Kintakas C, McCulloch DR. Emerging roles for ADAMTS5 during development and disease. Matrix Biol 2011; 30 (5-6): 311-317
    CrossrefPubMedSearch in Google Scholar
  • 24 Boesgaard TW, Gjesing AP, Grarup N. et al; EUGENE2 Consortium. Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients–EUGENE2 study. PLoS One 2009; 4 (09) e7236
    CrossrefPubMedSearch in Google Scholar
  • 25 Trombetta M, Bonetti S, Boselli ML. et al. PPARG2 Pro12Ala and ADAMTS9 rs4607103 as “insulin resistance loci” and “insulin secretion loci” in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4. Acta Diabetol 2013; 50 (03) 401-408
    CrossrefPubMedSearch in Google Scholar
  • 26 Polfus LM, Smith JA, Shimmin LC. et al. Genome-wide association study of gene by smoking interactions in coronary artery calcification. PLoS One 2013; 8 (10) e74642
    CrossrefPubMedSearch in Google Scholar
  • 27 Franceschini N, Giambartolomei C, de Vries PS. et al; MEGASTROKE Consortium. GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. Nat Commun 2018; 9 (01) 5141
    CrossrefPubMedSearch in Google Scholar
  • 28 Wei M, Pan H, Guo K. Association between plasma ADAMTS-9 levels and severity of coronary artery disease. Angiology 2021; 72 (04) 371-380
    CrossrefPubMedSearch in Google Scholar
  • 29 Li T, Peng J, Li Q, Shu Y, Zhu P, Hao L. The mechanism and role of ADAMTS protein family in osteoarthritis. Biomolecules 2022; 12 (07) 959
    CrossrefPubMedSearch in Google Scholar